Addressing MDR requires a deeper understanding of the molecular mechanisms underlying resistance, particularly those involving cancer stem cells (CSCs) and their associated markers, such as cluster of differentiation 44 (CD44) variants. This evidence concerns the gene CD44 and cancer.